i"?Trillium Therapeutics completes dosing of patients in phase one study of TTI-1612.
M2 PHARMA-May 20, 2013-i" Trillium Therapeutics completes dosing of patients in phase one study of TTI-1612(C)2013 M2 COMMUNICATIONS
Trillium Therapeutics, a wholly owned subsidiary of Stem Cell Therapeutics, has completed the dosing of patients with interstitial cystitis/bladder pain syndrome in its first phase study of TTI-1612, it was reported on Friday.
The study will assess the safety and tolerability profile of single ascending doses of TTI-1612. It involved 28 patients who were also evaluated for pharmacokinetics and changes in disease symptoms.
The company has developed TTI-1612 to correct the dysfunction and restore the bladder epithelium to a normal, healthy state.
((Comments on this story may be sent to email@example.com)).END.PUB430>PDMay 20, 2013>JNM2 PHARMA.PRICEDATENOT APPLICABLE.DAY